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Objectives: The use of mechanical circulatory support to bridge pediatric patients to
cardiac transplantation presents unique challenges because of the difficult anatomy
and physiology in these patients.
Methods: The United Network for Organ Sharing provided deidentifed patient-level
data. The study population included 2532 transplantations performed on patients less
than 19 years old in status 1/1A/1B between 1995 and 2005. Mechanical circulatory
support was used in 431 patients: 241 (9.5%) received ventricular assist devices, 171
(6.8%) underwent extracorporeal membrane oxygenation, and 19 (0.8%) received
intra-aortic balloon pumps.
Results: Patients supported on ventricular assist devices had similar levels of hospi-
talization and intensive care use and less need for inotropic support (P , .0002)
than had those not needing support. Five- and 10-year posttransplantation survival
was better in patients receiving ventricular assist devices and patients not receiving
mechanical circulatory support than in patients receiving extracorporeal membrane
oxygenation or intra-aortic balloon pumping (P, .0001). Among mechanically sup-
ported patients, patients with a body surface area of less than 0.30 (odds ratio, 1.70;
95% confidence interval, 1.18–2.43) and those requiring extracorporeal membrane
oxygenation (odds ratio, 1.65; 95% confidence interval, 1.15–2.35) or intra-aortic
balloon pumping (odds ratio, 1.91; 95% confidence interval, 1.02–3.56) had higher
long-term mortality. The use of a ventricular assist device at transplantation did not
predict higher long-term, posttransplantation mortality.
Conclusions: Pediatric patients requiring a pretransplantation ventricular assist device
have long-term survival similar to that of patients not receivingmechanical circulatory
support. Early survival among patients undergoing extracorporeal membrane oxygen-
ation and infants is poor, reinforcing the need for improvements in device design and
physiologic management of infants and neonates.
T
he use of mechanical devices to bridge adults to heart transplantation has been
well established. Despite higher immunologic sensitization in mechanically
bridged patients,1,2 long-term posttransplantation survival has been similar
to that of patients transplanted without mechanical circulatory support (MCS).1-4
Pediatric patients, because of both their smaller size and their often complex anatomy
and physiology, present a unique set of challenges that has resulted in a slower
adoption of MCS in this population.
Historically, extracorporeal membrane oxygenation (ECMO) has been used to sup-
port pediatric patients with end-stage heart failure. Children with heart failure have
been supported for significantly longer on ECMO than have adults.5-7 More recently,
the development of ventricular assist devices (VADs) suitable for implantation into
children has increased VAD use in these patients.8 Heretofore, most reports of
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TXAbbreviations and Acronyms
BSA 5 body surface area
CI 5 confidence interval
ECMO 5 extracorporeal membrane oxygenation
IABP 5 intra-aortic balloon pump
MCS 5 mechanical circulatory support
OR 5 odds ratio
UNOS 5 United Network for Organ Sharing
VAD 5 ventricular assist device
VAD use in the pediatric population have been anecdotal,
and few reports have directly compared the variety of options
for MCS in this population.
This report uses data from the United Network for Organ
Sharing (UNOS) database to assess posttransplantation out-
comes in patients requiringMCS at transplantation. Our goals
were to (1) compare the clinical status at transplantation of
patients with the various methods of MCS and (2) to identify
risk factors for short- and long-termmortality in these groups.
Materials and Methods
Data Collection
UNOS provided deidentified patient-level data from the Thoracic
Registry (data source no. 021606-4). Use of these data is consistent
with the regulations of our university’s institutional review board.
Records with incomplete data were excluded from analyses requir-
ing those data points.
Study Population
The study population consists of 2532 transplantations performed
on patients less than 19 years of age in status 1/1A/1B between
January 1, 1995, and December 31, 2005. Patients were stratified
by the presence and type of MCS at the time of transplantation:
none, VAD, ECMO, or intra-aortic balloon pump (IABP).
Data Analysis
Data were analyzed by using SAS 9.13 software for Windows (SAS
Institute, Cary, NC). The primary outcome was survival; other out-
comes were 30-day mortality and in-hospital complications. Contin-
uous variables are reported as means6 standard deviation and were
compared by using the Student t test (with the Bonferroni correc-
tion). Ordinal variables were compared by using the c2 test. All
P values are 2-sided. Multivariate regression (stepwise, P , .05)
was also performed. Kaplan–Meier analysis and Cox proportional
hazards regression (stepwise, P , .05) were used for time-to-event
analysis; patients without accurate follow-up times were excluded
from these analyses. Risk, odds, and hazard ratios are reported,
with 95% confidence intervals (CIs) in parentheses. Survival func-
tion estimates for strata of the explanatory variables were calculated
by using the BASELINE statement of PROC PHREG.
Results
Baseline Demographics and Incidence of MCS Use
There were 1101 female and 1431 male patients; median age
was 5 years (range, 0–18 years). Of 2532 patients, 431422 The Journal of Thoracic and Cardiovascular Surgery c Feb(17.0%) required MCS, either VAD (241 [9.5%] patients),
ECMO (171 [6.8%] patients), or IABP (19 [0.8%] patients),
at transplantation. Baseline demographics and clinical data
are shown in Table 1. Over the study period, the total number
of transplantations and the percentage of patients requiring
MCS have increased (P 5 .0013, Figure 1).
In-hospital Complications
Patients receiving ECMO had a higher incidence of postop-
erative complications before discharge than had those with
VADs, including cardiac reoperation (15.4% vs 12.7%;
odds ratio [OR], 1.26; 95% CI, 0.71–2.24), need for dialysis
(17.2% vs 9.1%; OR, 2.09; 95% CI, 1.16–3.80), drug-treated
postoperative infection (48.2% vs 32.1%; OR, 1.97; 95% CI,
1.30–2.97), and noncardiac surgical procedures (30.7% vs
17.2%; OR, 2.13; 95% CI, 1.32–3.44). Among all patients,
these complications resulted in high 30-day posttransplanta-
tion mortality (Table 2).
Early Mortality
Predictors of 30-day mortality included age less than 1 year
(OR, 1.72; 95% CI, 1.29–2.30), body surface are (BSA) of
less than 1.00 m2 (OR, 1.64; 95% CI, 1.18–2.27), a diagnosis
of congenital heart disease (OR, 2.15; 95% CI, 1.60–2.88),
and poor pretransplantation clinical status as reflected in
the need for ECMO (OR, 3.75; 95% CI, 2.53–5.57), prosta-
glandin E infusion (OR, 1.73; 95% CI, 1.16–2.58), ventilator
support (OR, 2.62; 95% CI, 1.94–3.52), intensive care (OR,
1.62; 95% CI, 1.15–2.27), and recent transfusions (OR, 2.05;
95% CI, 1.50–2.81). Donor variables did not contribute to
early mortality (data not shown). Multivariate analysis
confirmed the poor early survival among patients with poor
clinical status (Table 3). Subset analysis was performed of
patients without congenital heart disease. In this population
the need for ECMO (OR, 2.88; 95% CI, 1.46–5.68) but not
the need for a VAD (OR, 1.14; 95% CI, 0.62–2.10) remained
strong predictors of early mortality.
Long-term Mortality
All patients. Ten-year survival for all patients was 56.8%.
Patients with VADs and those in the group receiving noMCS
had better long-term survival (Figure 2); analysis of noncon-
genital patients was limited by small sample size, but there
was a similar trend (see Figure E1). In multivariate analysis
both of these groups continued to have better long-term
outcomes (Table 4).
Figure 2 demonstrates a late drop off in survival among
the patients undergoing VAD between 5 and 10 years after
transplantation. Among patients surviving at least 5 years,
the primary predictor of death was age greater than 13 years
(OR, 4.27; 95% CI, 2.47–7.38). Patients older than 13 years
had poor long-term survival (88.0% at 1 year, 66.0% at 5
years, and 44.6% at 10 years) compared with other age
groups (83.3%, 71.9%, and 62.1%, respectively; P5 .0070)ruary 2008
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Variable
Overall
(n 5 2532) nMCS (n 5 2101) VAD (n 5 241) ECMO (n 5 171) IABP (n 5 19)
Sex (male) 1431 (56.5%)
Waiting list
Days on waiting list 77.4 (70.8 to 83.8)yz 84.7 (65.5 to 103.9)x 33.3 (10.5 to 56.0)yx 17.3 (250.0 to 85.5)z
Days as status
1/1A/1B
46.5 (43.75 to 49.2)yz 58.4 (50.3 to 66.5)x 21.2 (11.1 to 30.8)yx 8.0 (220.7 to 36.8)z
Percentage time
as status 1/1A/1B
85.4% (84.1 to 86.7) 90.6% (86.8 to 94.4) 89.6% (85.1 to 94.1) 88.7% (75.2 to 100)
Age at
transplantation (y)
6.7 6 6.6 6.3 (6.0 to 6.6)yz 12.2 (11.4 to 13.0)*x 3.8 (2.9 to 4.8)yx 12.6 (9.7 to 15.4)zx
Weight at
transplantation (kg)
27.3 6 26.3 24.9 (23.6 to 26.4)*z 52.9 (48.9 to 57.0)*x 16.8 (11.9 to 21.7)x 50.6 (36.0 to 65.2)z
BSA at
transplantation (m2)
0.87 6 0.61 0.82 (0.79 to 0.84)*z 1.45 (1.38 to 1.53)*x 0.63 (0.54 to 0.73)x 1.40 (1.13 to 1.67)z
Cause of heart failure
Congenital heart
disease
1079 (42.6%) 954 (45.4%) 33 (13.7%) 90 (52.6%) 2 (10.5%)
Dilated
cardiomyopathy
1115 (44.0%) 857 (40.8%) 180 (74.7%) 66 (38.6%) 12 (63.2%)
Retransplantation 133 (5.3%) 115 (5.5%) 11 (4.6%) 5 (2.9%) 2 (10.5%)
Other or unspecified 205 (7.1%) 175 (8.4%) 17 (6.8%) 10 (5.9%) 3 (15.8%)
Clinical status
at transplantation
Cardiac index
(L $ min21 $ m22
most recent)
3.2 (3.1 to 3.4) 2.5 (2.1 to 3.0) 3.1 (2.1 to 4.2) 2.0 (0.6 to 3.5)
Inotropic support 1463 (57.8%) 1341 (64.0%)*yz 111 (46.1%)*x 144 (84.2%)yx 18 (94.7%)z
Ventilator dependent 565 (22.4%) 371 (17.7%)yz 45 (18.7%)x 139 (81.3%)yx 10 (52.6%)z
Hospitalized 2059 (82.4%) 1653 (80.0%)*yz 217 (90.0%)*x 171 (100.0%)yx 19 (100.0%)z
In Intensive Care Unit 1714 (68.6%) 1349 (65.3%)*yz 179 (74.3%)*x 168 (98.3%)yx 18 (94.8%)z
Transfusion required
since listing
864 (39.2%) 562 (31.0%)*y 160 (74.7%)*x 136 (85.0%)yx 6 (35.3%)
Past medical history
Chronic renal
insufficiency
102 (4.0%) 64 (3.1%)*y 17 (7.1%)* 19 (11.1%)y 2 (10.5%)
Stroke 85 (3.4%) 51 (2.5%)*y 20 (8.5%)* 13 (7.8%)y 1 (5.3%)
Donor variables
Donor age (y) 9.2 (8.5 to 9.7)*yz 18.6 (16.8 to 20.4)*x 8.2 (6.0 to 10.4)yx 27.7 (21.2 to 34.2)z
Ischemic time (h) 3.6 (3.6 to 3.7)z 3.4 (3.2 to 3.6) 3.6 (3.5 to 3.9) 2.9 (2.3 to 3.5)z
Overall means are presented as 6 standard error; otherwise, numbers in parentheses represent 95% confidence intervals. nMCS, No mechanical support;
VAD, ventricular assist device; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; BSA, body surface area. *P , .05 for com-
parison of no mechanical support to ventricular assist device. yP , .05 for comparison of no mechanical support to extracorporeal membrane oxygenation.
zP, .05 for comparison of no mechanical support to intra-aortic balloon pump. xP, .05 for comparison of ventricular assist device to extracorporeal mem-
brane oxygenation.TXPatients requiring MCS. Among patients requiring
MCS, Cox hazards for poor long-term survival included
a BSA of less than 0.30 m2 (hazard ratio [HR], 1.70; 95%
CI, 1.18–2.43) and the need for ECMO (HR, 1.65; 95% CI,
1.15–2.35) or IABP (HR, 1.91; 95% CI, 1.02–3.56) at trans-
plantation. Predicted survival curves based on patient size
and need for mechanical support demonstrate the significant
effect of these factors in determining long-term outcomes
(Figure 3) Cox regression of patients without congenital heartThe Journal of Thodisease revealed similar predictors of poor posttransplanta-
tion survival (see Table E1).
Primary causes of death among patients requiring VADs
did not differ significantly from those among patients not
requiring mechanical support (graft failure, 31.3%; infection,
6.0%; cardiac arrest, 7.6%;other cardiovascular causes, 10.5%;
multiple organ failure, 6.1%; and noncompliance, 4.6%). In
patients with ECMO, death more often resulted frommultiple
organ failure (16.9%; OR, 2.43; 95% CI, 1.22–4.86).racic and Cardiovascular Surgery c Volume 135, Number 2 423
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Figure 1. Histogram illustrating the
number of transplantations (status 1/
1A/1B, age #18 years) performed by
year. Transplantations requiring me-
chanical support are shown in cross-
hatching, and all others are shown in
white. The line indicates the percent-
age of transplantations requiring me-
chanical support.Discussion
This study demonstrates that the use of VADs in children re-
sults in excellent long-term posttransplantation survival. This
corroborates the results from the recent study by Blume and
colleagues,8 with comparable 10-year survival rates of ap-
proximately 50% to 60% in all patients, including those
with VADs. The survival curves clearly demonstrate that
the largest risk of mortality occurs in the immediate postop-
erative period. In this range outcomes among patients requir-
ing support with VADs were nearly identical to those of
patients not requiring support.
The late drop off in survival apparent in the VAD group
(Figure 1) appears to be attributable largely to the overrepre-
sentation of older patients (.13 years) in that group. These
older patients were at higher risk for transplant atherosclero-
sis and consequent graft failure over the long term. We spec-
ulate that this is largely due to poor compliance with the424 The Journal of Thoracic and Cardiovascular Surgery c Febimmunosuppressive regimen in the adolescent population,
a phenomenon previously described both in heart transplan-
tation and abdominal organ transplantation.9,10
Although VADs were associated with excellent posttrans-
plantation outcomes, similar outcomes were not seen in
patients bridged with ECMO. Previous series have demon-
strated the marginal survival associated with the use of
ECMO, whether for temporary postcardiotomy support7,11
or longer-term bridge to transplantation. In the series pub-
lished by Fiser and associates,12 only 34% of patients could
be successfully bridged to transplantation with ECMO.
Although slightly better results were reported by the group
from Michigan, still only 57% of listed patients survived to
transplantation.13 Our results demonstrate that the high risk
of death associated with the use of ECMO does not end
when the device is explanted and a new heart is implanted.
Especially in the first 30 days after transplantation, patientsTABLE 2. High risk of 30-day mortality with in-hospital complications for pediatric heart transplant recipients (<19 years
old) between 1995 and 2005
In-hospital complications 30-d Mortality P value Odds ratio
95% Confidence
interval
Cardiac reoperation 53/201 (26.4%) ,.0001* 5.46 3.81–7.82
Dialysis 54/181 (29.8%) ,.0001* 6.70 4.66–9.64
Drug-treated infection 77/672 (11.5%) ,.0001* 1.94 1.43–2.65
PPM 4/36 (11.1%) .4708 1.47 0.51–4.20
Stroke 10/55 (15.4%) .0146* 2.31 1.16–4.62
Other procedures 49/347 (14.1%) ,.0001* 2.36 1.66–3.34
Retransplantation 0/13 (0.0%) 0.2829 NA
PPM, Permanent pacemaker implantation; NA, not applicable. *P , .05.ruary 2008
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recipients (<19 years old) between 1995 and 2005
Variables Parameter estimate Standard error P value Odds ratio 95% Confidence interval
Intercept 141.0 56.5394 .0126
Later year of transplantation (per year) 20.0721 0.0283 .0108 0.93* 0.88–0.98
ECMO at transplantation 0.8979 0.2652 .0007 2.45 1.46–4.13
Dilated cardiomyopathy 21.0251 0.2199 ,.0001 0.36 0.23–0.55
Ventilator dependent at transplantation 0.5748 0.2042 .0049 1.78 1.19–2.65
Chronic renal insufficiency 1.0189 0.3124 .0011 2.77 1.50–5.11
ECMO, Extracorporeal membrane oxygenation. *Odds ratio reported for the year of transplantation indicates the risk associated with each later year.undergoing ECMO before the operation had higher rates of
end-organ failure (especially renal failure) and incurred a re-
sultant higher mortality rate. Notably, the effect of ECMO on
early posttransplantation survival was independent of the
cause of heart failure.
After this early period, the survival curves among all 3
groups (those without MCS, ECMO, and VAD) are parallel,
and ECMO ceases to be a predictor of poor outcome among
patients surviving the initial 30 days. Thus, those patients
who reach transplantation with adequate end-organ function
and survive the perioperative period appear to have equiva-
lent long-term outcomes, regardless of the need for or type
of mechanical support.
The poor clinical and functional status of patients bridged
with ECMO can be clearly seen in the high rate of ventilator
and inotropic support and in the nearly universal need for
intensive care. The high requirement for inotropic support
in patients using ECMO illustrates the poor ventricular offloading and marginal hemodynamics provided by venoarte-
rial ECMO. In contrast, patients with VADs had a signifi-
cantly lower need for inotropes and had hospitalization and
intensive care rates nearly identical to those of patients not
requiring mechanical support.
Unfortunately, although VAD implantation had better
outcomes than those with ECMO independent of patient
size, the smallest patients continued to do poorly with me-
chanical support, whether VAD or ECMO. It is likely that
most of the patients with BSAs of less than 0.30 m2 included
in the study population were supported by centrifugal pumps
rather than pulsatile VADs. Such pumps do not convey the
same advantages as the pulsatile VADs, including patient
mobility and improved rates of extubation and hospital dis-
charge, and therefore might contribute to the poorer outcomes
in this population. These results can improvewith the ongoing
development of VADs specifically designed for implanta-
tion into the pediatric population.TX0%
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Figure 2. Kaplan–Meier curve illustrat-
ing 10-year survival stratified by the
need for and type of mechanical circu-
latory support. Vertical bars indicate
95% confidence intervals of the sur-
vival function at selected time points.
The number of patients at risk at each
time point is given below the graph
(P < .0001).
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TXTABLE 4. Cox proportional hazards regression of posttransplantation mortality among pediatric heart transplant recipients
(<19 years old) between 1995 and 2005
Variable Parameter estimate Standard error P value Hazard ratio
95% Confidence
interval
Age 13–18 y 0.31067 0.08677 .0003 1.364 1.151–1.617
ECMO at transplantation 0.57979 0.13983 ,.0001 1.786 1.358–2.349
IABP at transplantation 0.58230 0.29495 .0484 1.790 1.004–3.191
Chronic renal insufficiency 0.49858 0.16988 .0033 1.646 1.180–2.297
Ventilator dependent
at transplantation
0.33849 0.09921 .0006 1.403 1.155–1.704
ECMO, Extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump.Limitations
These data have several limitations. First, long-term follow-
up (between 5 and 10 years) is only available in a small num-
ber of patients, and therefore outcomes in that time period are
less amenable to detailed analysis. Second, the limited time
points for collection of data in the UNOS registry (at listing,
at transplantation, and at follow-up) preclude the analysis of
clinical status at the time of device implantation or over the
course of mechanical support.
As such, we could not analyze the length of time
supported by a particular device, which might have been
a particularly strong predictor of end-organ dysfunction
and poor outcome. More importantly, without information
about clinical status at device implantation, we are unable
to answer the most important questions: ‘‘Which patients
are likely to benefit from mechanical support, and when
should it be initiated?’’ The nature of the UNOS dataset fur-
ther limits our ability to answer these questions because it
does not capture those patients who have a VAD but arenot bridged to transplantation (either because they recover
or die before listing).
Finally, although data submission at these time points is
mandated, the completeness of submitted data is not; there-
fore several variables that might have been of interest were
insufficiently populated and were eliminated from analysis.
Fortunately, several of these limitations, most impor-
tantly the question of clinical status at initiation of mechan-
ical support, might soon be addressed by the Interagency
Registry for Mechanically Assisted Circulatory Support
database.14
Conclusions
In conclusion, we have examined the UNOS thoracic organ
transplantation registry and evaluated the outcomes of pedi-
atric patients requiring MCS at the time of transplantation.
This has shown that long-term posttransplantation survival
in patients receiving VADs is similar to that seen in those
not requiring mechanical support. In contrast, patients0%
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Figure 3. Ten-year survival function
estimates by patient size and need for
mechanical support.
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of end-organ dysfunction at transplantation and a correspond-
ingly high mortality, especially in the immediate posttrans-
plantation period. Despite the excellent outcomes overall
with the use of VADs, the smallest patients continue to
have poor early survival independent of the type of support
used, and it remains to be seen whether the newer devices
will mitigate this difference.
We thank UNOS for supplying these data and Katarina Ander-
son for her assistance with our analysis.
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Figure E1. Kaplan–Meier curve shows
10-year survival stratified by the need
for and type of mechanical circulatory
support among patients without con-
genital heart disease. Vertical bars
indicate 95% confidence intervals of
the survival function at selected time
points. The number of patients at risk
at each time point are given below
the graph (P 5 .0289).
TABLE E1. Cox proportional hazards regression of long-term survival among patients without congenital heart disease*
Variable Parameter estimate Standard error P value Hazard ratio 95% Confidence interval
Age 13–18 y 0.45611 0.11647 ,.0001 1.578 1.256–1.983
ECMO at transplantation 0.36364 0.22684 .1089 1.439 0.922–2.244
IABP at transplantation 0.56106 0.32533 .0846 1.753 0.926–3.316
Chronic renal insufficiency 0.40537 0.23971 .0908 1.500 0.938–2.399
Ventilator dependent
at transplantation
0.36961 0.14302 .0098 1.447 1.093–1.915
Year of transplantation
(per year)
20.04792 0.02219 .0308 0.953 0.913–0.996
ECMO, Extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump. *Performed by using forward stepwise selection. Because of the smaller sam-
ple size associated with excluding patients with congenital heart disease, selection criteria were broadened to a P value of less than .20.427.e1 The Journal of Thoracic and Cardiovascular Surgery c February 2008
